An evaluation of efficacy and safety of Statin versus Bempedoic acid versus Bempedoic acid added Ezetemibe in dyslipidemic North Indian population.

An evaluation of efficacy and safety of Statin versus Bempedoic acid versus Bempedoic acid plus Ezetemibe in dyslipidemic North Indian population at tertiary care centre. - BEMPE

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/04/084658

Enrollment

180

Registered

2025-04-13

Start date

Unknown

Completion date

Unknown

Last updated

2025-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E782- Mixed hyperlipidemia

Interventions

Control Intervention1: Statin versus Bempedoic acid versus Bempedoic acid plus Ezetemibe: Dyslipdemic patients will be divided in 3 groups. Gp 1 will be given Statin. Gp 2 will be given Bempedoic acid

Eligibility

Inclusion criteria

Inclusion criteria: dyslipidemic patients

Exclusion criteria

Exclusion criteria: pregnancy, lactation, renal failure, severe hepatic dysfunction, neurological disorders, on immunosuppressants

Design outcomes

Primary

Measure	Time frame
lipid profile, hsCRP, CPK-total, HbA1c. BMI, LFT, RFT.Timepoint: base line , 4 , 8 and 12 weeks of treatment	—

Secondary

Measure	Time frame
Timepoint:	—

Countries

India

Contacts

Public ContactVed Prakash

IMS-BHU Varanasi

sonivedgmc@bhu.ac.in8601741409

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026